Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) shares were up 10.2% during trading on Tuesday . The stock traded as high as $16.56 and last traded at $16.42. Approximately 118,927 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 224,239 shares. The stock had previously closed at $14.90.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. Guggenheim assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $45.00 target price on the stock. Stifel Nicolaus started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $32.00 target price on the stock. Finally, TD Cowen initiated coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating for the company.
View Our Latest Stock Analysis on SION
Sionna Therapeutics Stock Down 0.1 %
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
- Five stocks we like better than Sionna Therapeutics
- How to Invest in the Best Canadian Stocks
- 3 Undervalued Stocks You Can Buy at a Discount Now
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Why is the Ex-Dividend Date Significant to Investors?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.